Reply to van der Pluijm et al. Comment on “Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781”

Detalles Bibliográficos
Autores principales: Calfon-Peretz, Ortal, Weitzman, Rachel, Amitay, Moshe, Samson, Abraham O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Reply
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181780/
https://www.ncbi.nlm.nih.gov/pubmed/35683361
http://dx.doi.org/10.3390/jcm11112972
_version_ 1784723868141748224
author Calfon-Peretz, Ortal
Weitzman, Rachel
Amitay, Moshe
Samson, Abraham O.
author_facet Calfon-Peretz, Ortal
Weitzman, Rachel
Amitay, Moshe
Samson, Abraham O.
author_sort Calfon-Peretz, Ortal
collection PubMed
description
format Online
Article
Text
id pubmed-9181780
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91817802022-06-10 Reply to van der Pluijm et al. Comment on “Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781” Calfon-Peretz, Ortal Weitzman, Rachel Amitay, Moshe Samson, Abraham O. J Clin Med Reply MDPI 2022-05-25 /pmc/articles/PMC9181780/ /pubmed/35683361 http://dx.doi.org/10.3390/jcm11112972 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Reply
Calfon-Peretz, Ortal
Weitzman, Rachel
Amitay, Moshe
Samson, Abraham O.
Reply to van der Pluijm et al. Comment on “Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781”
title Reply to van der Pluijm et al. Comment on “Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781”
title_full Reply to van der Pluijm et al. Comment on “Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781”
title_fullStr Reply to van der Pluijm et al. Comment on “Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781”
title_full_unstemmed Reply to van der Pluijm et al. Comment on “Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781”
title_short Reply to van der Pluijm et al. Comment on “Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781”
title_sort reply to van der pluijm et al. comment on “weitzman et al. resistance to antimalarial monotherapy is cyclic. j. clin. med. 2022, 11, 781”
topic Reply
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181780/
https://www.ncbi.nlm.nih.gov/pubmed/35683361
http://dx.doi.org/10.3390/jcm11112972
work_keys_str_mv AT calfonperetzortal replytovanderpluijmetalcommentonweitzmanetalresistancetoantimalarialmonotherapyiscyclicjclinmed202211781
AT weitzmanrachel replytovanderpluijmetalcommentonweitzmanetalresistancetoantimalarialmonotherapyiscyclicjclinmed202211781
AT amitaymoshe replytovanderpluijmetalcommentonweitzmanetalresistancetoantimalarialmonotherapyiscyclicjclinmed202211781
AT samsonabrahamo replytovanderpluijmetalcommentonweitzmanetalresistancetoantimalarialmonotherapyiscyclicjclinmed202211781

Ejemplares similares